Protocol II versus protocol III given twice during reinduction therapy in children with medium risk ALL,Blood

当前位置： X-MOL 学术 › Blood › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Protocol II versus protocol III given twice during reinduction therapy in children with medium risk ALL
Blood ( IF 20.3 ) Pub Date : 2017-11-09 , DOI: 10.1182/blood-2017-05-782086
Franco Locatelli _{1,

2} , Maria Grazia Valsecchi ₃ , Anja Möricke ₄ , Martin Zimmermann ₅ , Bernd Gruhn ₆ , Andrea Biondi ₇ , Andreas E. Kulozik ₈ , Daniela Silvestri _{3,

9} , Nicole Bodmer ₁₀ , Maria Caterina Putti ₁₁ , Stefan Burdach ₁₂ , Concetta Micalizzi ₁₃ , Andrea Teigler-Schlegel ₁₄ , Jörg Ritter ₁₅ , Andrea Pession ₁₆ , Gunnar Cario ₄ , Stefan Bielack ₁₇ , Giuseppe Basso ₁₁ , Thomas Klingebiel ₁₈ , Luciana Vinti _{1,

2} , Carmelo Rizzari ₉ , Andishe Attarbaschi ₁₉ , Nicola Santoro ₂₀ , Rosanna Parasole ₂₁ , Georg Mann ₁₉ , Leonid Karawajew ₂₂ , Oskar A. Haas ₁₉ , Valentino Conter ₉ , Martin Schrappe ₄

Affiliation

Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy;
Department of Pediatric Science, University of Pavia, Pavia, Italy;
Medical Statistics Unit, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy;
Department of Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;
Department of Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany;
Department of Pediatrics, Jena University Hospital, Jena, Germany;
M. Tettamanti Research Center, Pediatric Clinic, University of Milan Bicocca, Monza, Italy;
Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Heidelberg, Germany;
Department of Pediatrics, Ospedale S. Gerardo, Monza, Italy;
Department of Pediatric Hematology/Oncology, University Hospital Zurich, Zurich, Switzerland;
Department of Pediatrics, University of Padova, Azienda Ospedaliera di Padova, Padova, Italy;
Department of Pediatric Hematology/Oncology, Technical University of Munich, Munich, Germany;
Division of Pediatric Hematology, IRCCS Ospedale Giannina Gaslini, Genova, Italy;
Department of Experimental Pathology and Cytology, Institute of Pathology, Giessen, Germany;
Department of Pediatric Hematology and Oncology, University Hospital Munster, Munster, Germany;
Department of Pediatrics, Sant’Orsola Hospital, University of Bologna, Bologna, Italy;
Department of Pediatric Hematology-Oncology, Olgahospital Stuttgart, Stuttgart, Germany;
Department of Children and Adolescent Medicine, Children's Hospital, Goethe University, Frankfurt, Germany;
Children’s Cancer Research Institute, St. Anna Children’s Hospital, Department of Pediatrics, Medical University of Vienna, Vienna, Austria;
Division of Pediatric Hematology/Oncology, Policlinico di Bari, Bari, Italy;
Division of Pediatric Hematology/Oncology, Pausillipon Hospital, Naples, Italy; and
Department of Pediatric Oncology/Hematology, Charité University Medical Center, Berlin, Germany

To the editor: Reinduction therapy (also known as delayed intensification, DI) is an essential part of childhood acute lymphoblastic leukemia (ALL) treatment.[1][1],[2][2] In Berlin-Frankfurt-Munster (BFM) studies, it includes same/similar drugs as those employed in induction therapy. The Children

中文翻译：

方案 II 与方案 III 在中危 ALL 儿童再诱导治疗期间给予两次

致编辑：再诱导治疗（也称为延迟强化，DI）是儿童急性淋巴细胞白血病（ALL）治疗的重要组成部分。 [1][1],[2][2] 在柏林-法兰克福-明斯特（BFM） ) 研究，它包括与诱导治疗中使用的药物相同/相似的药物。这些孩子

更新日期：2017-11-09

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>